TY - JOUR
T1 - Reduction in Developmental Coordination Disorder with Neonatal Caffeine Therapy
AU - Doyle, Lex W.
AU - Schmidt, Barbara
AU - Anderson, Peter J.
AU - Davis, Peter G.
AU - Moddemann, Diane
AU - Grunau, Ruth E.
AU - O'Brien, Karel
AU - Sankaran, Koravangattu
AU - Herlenius, Eric
AU - Roberts, Robin
AU - AUTHOR GROUP
AU - Asztalos, Elizabeth V.
AU - Barrington, Keith J.
AU - Dewey, Deborah
AU - Ohlsson, Arne
AU - Roberts, Robin S.
AU - Solimano, Alfonso
AU - Tin, Win
AU - Gent, Michael
AU - Fraser, William
AU - Hey, Edmund
AU - Perlman, Max
AU - Thorpe, Kevin
AU - Gray, Shari
AU - Chambers, Carole
AU - Costantini, Lorrie
AU - Yacura, Wendy
AU - McGean, Erin
AU - Scapinello, Lori
AU - D'Ilario, Judy
AU - Cairnie, Janice
AU - Dix, Joanne
AU - Adams, Beth
AU - Warriner, Erin
AU - Kim, Mee-Hai Marie
AU - Argus, Brenda
AU - Callanan, Kate
AU - Davis, Noni
AU - Duff, Julianne
AU - McDonald, Marion
AU - Hohn, Denise
AU - Lacy, Maralyn
AU - Haslam, Ross
AU - Barnett, Christopher
AU - Goodchild, Louise
AU - Lontis, Rosslyn
AU - Fraser, Simon
AU - Keng, Julie
AU - van Wassenaer, Aleid
AU - Houtzager, Bregje
AU - van Sonderen, Loekie
PY - 2014
Y1 - 2014
N2 - Objective To determine the effect of neonatal caffeine treatment on rates of developmental coordination disorder (DCD). Study design Children in the Caffeine for Apnea of Prematurity trial were assessed for motor performance (Movement Assessment Battery for Children [MABC]), clinical signs of cerebral palsy, and Full-Scale IQ at 5 years of age by staff who were unaware of the children's treatment group. DCD was defined as MABC <5th percentile in children with a Full-Scale IQ >69 who did not have a diagnosis of cerebral palsy. Results There were 1433 children with known MABC corrected-age percentile as well as known Full-Scale IQ at 5 years and cerebral palsy status, of whom 735 had been randomly assigned to caffeine and 698 to placebo therapy. The rate of DCD was lower in those treated with caffeine (11.3%) than in the placebo group (15.2%) (OR adjusted for center and baseline covariates, 0.71, 95% CI, 0.52-0.97; P = .032). Conclusions Neonatal caffeine therapy for apnea of prematurity reduces the rate of DCD at 5 years of age. As more children have DCD than have cerebral palsy, this is an important additional benefit from neonatal caffeine treatment
AB - Objective To determine the effect of neonatal caffeine treatment on rates of developmental coordination disorder (DCD). Study design Children in the Caffeine for Apnea of Prematurity trial were assessed for motor performance (Movement Assessment Battery for Children [MABC]), clinical signs of cerebral palsy, and Full-Scale IQ at 5 years of age by staff who were unaware of the children's treatment group. DCD was defined as MABC <5th percentile in children with a Full-Scale IQ >69 who did not have a diagnosis of cerebral palsy. Results There were 1433 children with known MABC corrected-age percentile as well as known Full-Scale IQ at 5 years and cerebral palsy status, of whom 735 had been randomly assigned to caffeine and 698 to placebo therapy. The rate of DCD was lower in those treated with caffeine (11.3%) than in the placebo group (15.2%) (OR adjusted for center and baseline covariates, 0.71, 95% CI, 0.52-0.97; P = .032). Conclusions Neonatal caffeine therapy for apnea of prematurity reduces the rate of DCD at 5 years of age. As more children have DCD than have cerebral palsy, this is an important additional benefit from neonatal caffeine treatment
U2 - 10.1016/j.jpeds.2014.04.016
DO - 10.1016/j.jpeds.2014.04.016
M3 - Article
C2 - 24840756
SN - 0022-3476
VL - 165
SP - 356-U193
JO - Journal of pediatrics
JF - Journal of pediatrics
IS - 2
ER -